A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs.

Abstract : Chikungunya virus (CHIKV) is a globally spreading alphavirus against which there is no commercially available vaccine or therapy. Here we use a genome-wide siRNA screen to identify 156 proviral and 41 antiviral host factors affecting CHIKV replication. We analyse the cellular pathways in which human proviral genes are involved and identify druggable targets. Twenty-one small-molecule inhibitors, some of which are FDA approved, targeting six proviral factors or pathways, have high antiviral activity in vitro, with low toxicity. Three identified inhibitors have prophylactic antiviral effects in mouse models of chikungunya infection. Two of them, the calmodulin inhibitor pimozide and the fatty acid synthesis inhibitor TOFA, have a therapeutic effect in vivo when combined. These results demonstrate the value of loss-of-function screening and pathway analysis for the rational identification of small molecules with therapeutic potential and pave the way for the development of new, host-directed, antiviral agents.
Document type :
Journal articles
Complete list of metadatas

Cited literature [50 references]  Display  Hide  Download

https://hal-pasteur.archives-ouvertes.fr/pasteur-01515939
Contributor : Marie-Claire Rozier <>
Submitted on : Friday, April 28, 2017 - 12:11:40 PM
Last modification on : Friday, April 12, 2019 - 3:42:05 PM
Long-term archiving on : Saturday, July 29, 2017 - 1:18:18 PM

File

ncomms11320.pdf
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

Citation

Alexander Karlas, Stefano Berre, Thérèse Couderc, Margus Varjak, Peter Braun, et al.. A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs.. Nature Communications, Nature Publishing Group, 2016, 7, pp.11320. ⟨10.1038/ncomms11320⟩. ⟨pasteur-01515939⟩

Share

Metrics

Record views

501

Files downloads

321